Photo by flashdantz from unsplash
Due to its consistent elevation in polycystic ovary syndrome (PCOS) and correlation with polycystic ovarian morphology (PCOM), anti‐Mullerian hormone (AMH) has been proposed as a marker of the syndrome. However,… Click to show full abstract
Due to its consistent elevation in polycystic ovary syndrome (PCOS) and correlation with polycystic ovarian morphology (PCOM), anti‐Mullerian hormone (AMH) has been proposed as a marker of the syndrome. However, prior studies reporting thresholds of AMH for a PCOS diagnosis have been limited by small sample size, inappropriate controls, and heterogeneous AMH assays. We sought to evaluate the suitability of a standardized AMH assay as a biomarker of PCOS.
Keywords:
hormone;
polycystic ovary;
stratified thresholds;
ovary syndrome;
age stratified;
syndrome
Journal Title: Clinical Endocrinology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Endocrinology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!